# bib

id: cord-311622-fqptz6v3
author: Porfidia, Angelo
title: Venous thromboembolism in COVID‐19 patients
date: 2020-04-15
extension: .txt
mime: text/plain
words: 622
sentence: 23
flesch: 45
cache: cache/cord-311622-fqptz6v3.txt
txt: txt/cord-311622-fqptz6v3.txt
summary:
  Such hypothesis is strengthened by the fact that mortality correlates with D-dimer levels among heparin non-users, although we are aware that high D-dimer levels may be due to many factors in COVID-19 patients and do not necessarily depend on the presence of VTE. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID‐19 who have “sepsis‐induced coagulopathy”.


id: cord-261629-ylajz928
author: Demirci, Ufuk
date: 2020-07-10
extension: .txt
mime: text/plain
words: 628
sentence: 23
flesch: 33
cache: cache/cord-261629-ylajz928.txt
txt: txt/cord-261629-ylajz928.txt
title:
  Reducing the Risk of Venous Thrombosis During Self-Isolation and COVID-19 Pandemic for Patients With Cancer: Focus on Home Exercises Prescription

summary:
  Ufuk Demirci https://orcid.org/0000-0001-6923-1470 Elif G. Umit https://orcid.org/0000-0001-5589-3000 The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update American College of Sports Medicine Resource Manual for Guidelines for Exercise Testing and Prescription The relationship of foot and ankle movements to venous return in the lower limb Guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients However, using of compression stocks in VTE prophylaxis is not recommended in outpatients with minor VTE risk factors.


id: cord-352793-50ym7h4t
author: Cui, Songping
title: Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia
date: 2020-05-06
extension: .txt
mime: text/plain
words: 1261
sentence: 71
flesch: 57
cache: cache/cord-352793-50ym7h4t.txt
txt: txt/cord-352793-50ym7h4t.txt
summary:
  The significant increase of D‐dimer in severe NCP patients is a good index for identifying high‐risk groups of VTE. [12] [13] [14] Sepsis is also a common cause of disseminated intravascular coagulation (DIC) 15 and the incidence of DIC in dead NCP patients was 71.4%.


id: cord-313243-pwmi765q
author: Middeldorp, Saskia
title: Incidence of venous thromboembolism in hospitalized patients with COVID‐19
date: 2020-07-27
extension: .txt
mime: text/plain
words: 1373
sentence: 48
flesch: 37
cache: cache/cord-313243-pwmi765q.txt
txt: txt/cord-313243-pwmi765q.txt
summary:
  We did not adjudicate deaths to identify fatal PE because almost all deaths were due to hypoxemic respiratory failure, which can be indistinguishable from fatal PE, whereas autopsies were rarely performed in COVID-19 patients. 12 Only 22% of COVID-19 patients received thrombosis prophylaxis, which is much less than expected according to guidelines on thrombosis prophylaxis in medical patients.


id: cord-257939-tgpsd3r7
author: Haider, Maryam B.
date: 2020-07-20
extension: .txt
mime: text/plain
words: 1502
sentence: 69
flesch: 42
cache: cache/cord-257939-tgpsd3r7.txt
txt: txt/cord-257939-tgpsd3r7.txt
title:
  A 46-Year-Old Woman Who Presented with Diabetic Ketoacidosis and COVID-19 Pneumonia with Multiple Pulmonary Thromboemboli: A Case Report

summary:
  It is suspected to be more prevalent in COVID-19 patients, especially those needing admission in the intensive care unit. The patient in discussion developed PE despite being on a prophylactic dose of heparin, suggesting that only a prophylactic dose may not be sufficient to prevent VTE in COVID-19 patients with higher inflammatory markers.


id: cord-282636-u0ea02fc
author: Zuo, Y.
title: Neutrophil extracellular traps and thrombosis in COVID-19
date: 2020-05-05
extension: .txt
mime: text/plain
words: 1709
sentence: 68
flesch: 29
cache: cache/cord-282636-u0ea02fc.txt
txt: txt/cord-282636-u0ea02fc.txt
summary:
  Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis Neutrophil extracellular traps promote deep vein thrombosis in mice In vivo characterization of neutrophil extracellular traps in various organs of a murine sepsis model Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Pandemic H1N1 influenza infection and vascular thrombosis Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Prominent changes in blood coagulation of patients with SARS-CoV-2 infection Biological basis and pathological relevance of microvascular thrombosis Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis Neutrophil extracellular traps promote thrombin generation through platelet-dependent and plateletindependent mechanisms Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases Netting neutrophils in autoimmune small-vessel vasculitis


id: cord-314259-26jriik0
author: Pizzolo, Francesca
date: 2020-08-06
extension: .txt
mime: text/plain
words: 2071
sentence: 80
flesch: 39
cache: cache/cord-314259-26jriik0.txt
txt: txt/cord-314259-26jriik0.txt
title:
  Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg

summary:
  Meanwhile, we can argue that early detection of DVT in COVID-19 patients may allow a more appropriate management, for example by shifting rapidly from standard thromboprophylaxis to full anticoagulant therapy in patients with high thrombotic burden, like the reported 3 subjects in whom CT-pulmonary angiography revealed pulmonary embolism. The findings of a high prevalence of DVT in patients taking the usual thromboprophylaxis and estimated at low risk of thrombotic complications according to the traditional risk assessment model (such as the Padua Prediction Score), emphasize some unsolved issues: i) potential SARS-CoV-2-related hypercoagulable state, ii) appropriate VTE risk stratification for hospitalized COVID-19 patients, and iii) the choice of anticoagulant agents and relative doses, which require further investigations [2] .


id: cord-351101-l8b2cv4z
author: Uppuluri, Ellen M
date: 2020-08-11
extension: .txt
mime: text/plain
words: 2170
sentence: 76
flesch: 34
cache: cache/cord-351101-l8b2cv4z.txt
txt: txt/cord-351101-l8b2cv4z.txt
title:
  Development of pulmonary embolism in a nonhospitalized patient with COVID-19 who did not receive venous thromboembolism prophylaxis

summary:
  National Institutes of Health website Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST guideline and expert panel report Implementation of a direct oral anticoagulation screening service at a large academic medical center provided by a pharmacist-managed antithrombosis clinic as a method to expand antithrombotic stewardship efforts Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Incidence of venous thromboembolism in hospitalized patients with COVID-19 Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence Blood coagulation, fibrinolysis and cellular haemostasis: venous thromboembolic events in hospitalized medical patients Pulmonary embolism: a complication of COVID 19 infection Rivaroxaban for thromboprophylaxis in acutely ill medical patients Extended thromboprophylaxis with betrixaban in acutely ill medical patients Rivaroxaban for thromboprophylaxis after hospitalization for medical illness American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis Considerations in prophylaxis and treatment of VTE in COVID-19 patients Search result ISTH interim guidance on recognition and management of coagulopathy in COVID-19 COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the Anticoagulation Forum COVID-19) treatment guidelines.


id: cord-346135-uidvtpjw
author: Parks, Anna L.
date: 2020-09-16
extension: .txt
mime: text/plain
words: 2188
sentence: 93
flesch: 26
cache: cache/cord-346135-uidvtpjw.txt
txt: txt/cord-346135-uidvtpjw.txt
title:
  COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic

summary:
  key: cord-346135-uidvtpjw authors: Parks, Anna L.; Auerbach, Andrew D.; Schnipper, Jeffrey L.; Anstey, James E.; Sterken, David G.; Hecht, Todd E.H.; Fang, Margaret C. title: COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic date: 2020-09-16 journal: Thromb Res DOI: 10.1016/j.thromres.2020.09.018 sha: doc_id: 346135 cord_uid: uidvtpjw As the Coronavirus disease 2019 (COVID-19) pandemic spread to the US, so too did descriptions of an associated coagulopathy and thrombotic complications. Representatives from participating institutions submitted inpatient protocols for incorporation in the analysis between April 10, 2020 and May 5, 2020.


id: cord-291483-ni6toh8c
author: Kermani-Alghoraishi, Mohammad
title: A Review of Venous Thromboembolism Phenomena in COVID-19 Patients
date: 2020-08-28
extension: .txt
mime: text/plain
words: 1977
sentence: 62
flesch: 25
cache: cache/cord-291483-ni6toh8c.txt
txt: txt/cord-291483-ni6toh8c.txt
summary:
  Therefore, in this review, the pathogens, epidemiology, diagnosis and therapeutic management of COVID-19 patients with VTE disease are discussed. The above theory could explain pulmonary embolism in COVID-19 patients who are not in critical condition.


id: cord-320822-etibcspx
author: Wright, Franklin L.
title: Fibrinolysis Shutdown Correlates to Thromboembolic Events in Severe COVID-19 Infection
date: 2020-05-15
extension: .txt
mime: text/plain
words: 2421
sentence: 74
flesch: 24
cache: cache/cord-320822-etibcspx.txt
txt: txt/cord-320822-etibcspx.txt
summary:
  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Procoagulant activity during viral infections Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Hypercoagulability of COVID-19 patients in Intensive Care Unit. Patients with fibrinolysis shutdown had a 40% rate of VTE compared to 5% in patients without shutdown (p=0.013).


id: cord-335020-at43c8q7
author: Porfidia, Angelo
date: 2020-05-04
extension: .txt
mime: text/plain
words: 2419
sentence: 76
flesch: 35
cache: cache/cord-335020-at43c8q7.txt
txt: txt/cord-335020-at43c8q7.txt
title:
  Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies

summary:
  key: cord-335020-at43c8q7 authors: Porfidia, Angelo; Pola, Roberto title: Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies date: 2020-05-04 journal: J Thromb Thrombolysis DOI: 10.1007/s11239-020-02125-4 sha: doc_id: 335020 cord_uid: at43c8q7 nan The disease caused by coronavirus SARS-CoV-2, named COVID-19, has become a global emergency. In this article, we discuss the many doubts currently existing on the use of heparins and the correct prevention and diagnosis of VTE in COVID-19 patients, with physicians that juggle between pragmatic choices, different suggestions being released on a daily by hospital and medical societies, and the lack of solid evidence or guidelines.


id: cord-277201-jzjxsetx
author: Mazo, Jahinover
title: More than Just Pneumonia: Acute Pulmonary Embolism in Two Middle-Aged Patients with COVID-19
date: 2020-07-30
extension: .txt
mime: text/plain
words: 2652
sentence: 137
flesch: 40
cache: cache/cord-277201-jzjxsetx.txt
txt: txt/cord-277201-jzjxsetx.txt
summary:
  Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT Angiography Pulmonary embolism and increased levels of d-dimer in patients with coronavirus disease e emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis Characteristics of ischaemic stroke associated with COVID-19 e use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China romboinflammation and the hypercoagulability of COVID-19 e procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome Hyperinflammation and derangement of renin-angiotensinaldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis Cytokines as Regulators of Coagulation Prevention, diagnosis, and treatment of VTE in patients with COVID-19 Predictive and associative models to identify hospitalized medical patients at risk for VTE Modified IM-PROVE VTE risk score and elevated D-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score rombosis risk assessment as a guide to quality patient care romboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic According to data from China, where the virus originated, 87% of COVID-19 patients were between the age 30-79 years


id: cord-000716-fhm8abxp
author: Wang, Hao
title: Analysis on the Pathogenesis of Symptomatic Pulmonary Embolism with Human Genomics
date: 2012-07-11
extension: .txt
mime: text/plain
words: 2774
sentence: 109
flesch: 38
cache: cache/cord-000716-fhm8abxp.txt
txt: txt/cord-000716-fhm8abxp.txt
summary:
  In addition, we also found that the number of CD3+T cells and CD8+T cells was dramatically reduced in a series of acute PE patients and cytological findings also supported the results from genomics studies on PE patients (27) . Genomic data showed no damage to vascular endothelial cells in PE patients.


id: cord-301493-32l52q3s
author: Hill, Jason B.
title: Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study
date: 2020-11-02
extension: .txt
mime: text/plain
words: 3232
sentence: 121
flesch: 40
cache: cache/cord-301493-32l52q3s.txt
txt: txt/cord-301493-32l52q3s.txt
summary:
  Although our overall rate of VTE in hospitalized patients was low, half of our cases occurred in patients who were receiving effective VTE prophylaxis prior to their VTE. Is the recommendation to use high-dose heparin for thromboprophylaxis justified? VTE incidence and risk factors in patients with severe sepsis and septic shock Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients Pulmonary embolism in patients with COVID-19 Thrombosis in hospitalized patients with COVID-19 in a New York City health system Postdischarge venous thromboembolism following hospital admission with COVID-19 High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study


id: cord-327370-zo0n8wf6
author: Vadukul, Prakash
date: 2020-09-13
extension: .txt
mime: text/plain
words: 3120
sentence: 145
flesch: 34
cache: cache/cord-327370-zo0n8wf6.txt
txt: txt/cord-327370-zo0n8wf6.txt
title:
  Massive pulmonary embolism following recovery from COVID-19 infection: inflammation, thrombosis and the role of extended thromboprophylaxis

summary:
  COVID-19 infection: origin, transmission, and characteristics of human coronaviruses Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation Blood coagulation in immunothrombosis-At the frontline of intravascular immunity Coagulation abnormalities and thrombosis in patients with COVID-19 Interleukin 6 and haemostasis Interleukin 6 regulates psoriasiform inflammationassociated thrombosis Interleukin-6 in COVID-19: a systematic review and metaanalysis SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? key: cord-327370-zo0n8wf6 authors: Vadukul, Prakash; Sharma, Deepak S; Vincent, Paul title: Massive pulmonary embolism following recovery from COVID-19 infection: inflammation, thrombosis and the role of extended thromboprophylaxis date: 2020-09-13 journal: BMJ Case Rep DOI: 10.1136/bcr-2020-238168 sha: doc_id: 327370 cord_uid: zo0n8wf6 COVID-19 is the infectious disease caused by a recently discovered SARS-CoV-2.


id: cord-328220-toeq4xq0
author: Smith, Kelly
date: 2020-07-06
extension: .txt
mime: text/plain
words: 3213
sentence: 128
flesch: 34
cache: cache/cord-328220-toeq4xq0.txt
txt: txt/cord-328220-toeq4xq0.txt
title:
  Practical Considerations in Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19

summary:
  Understanding of these abnormalities is continually evolving, but these conditions may pose a risk to COVID-19 patients beyond the risk typically seen in critically ill patients. 3, 4 Poissy et al 5 reported an increased incidence of pulmonary embolism (PE) amongst COVID-19 patients admitted to an intensive care unit.


id: cord-000728-ligqoj24
author: Duan, Qianglin
title: Symptomatic Venous Thromboembolism Is a Disease Related to Infection and Immune Dysfunction
date: 2012-07-26
extension: .txt
mime: text/plain
words: 3410
sentence: 149
flesch: 46
cache: cache/cord-000728-ligqoj24.txt
txt: txt/cord-000728-ligqoj24.txt
summary:
  In addition, flow cytometry was performed to investigate the changes in immune cells in VTE patients, which aimed to validate the results from genome analysis. No significant difference in age was found between PE patients and control patients (P>0.05).


id: cord-306997-84pjfawk
author: Melazzini, Federica
date: 2020-11-08
extension: .txt
mime: text/plain
words: 3667
sentence: 143
flesch: 39
cache: cache/cord-306997-84pjfawk.txt
txt: txt/cord-306997-84pjfawk.txt
title:
  Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy

summary:
  Since 100% of VTE patients had a Padua score greater than 4, we suggest performing upper and lower limb venous ultrasound in COVID-19 patients with a score > 4, as well as routinely in ICU patients to identify and treat DVT as soon as possible. Supplementary Table 1 shows characteristics and differences between VTE patients admitted to intensive care unit (ICU) and VTE general ward patients.


id: cord-342603-k0f33p3l
author: Spyropoulos, Alex C.
date: 2020-05-27
extension: .txt
mime: text/plain
words: 3805
sentence: 110
flesch: 22
cache: cache/cord-342603-k0f33p3l.txt
txt: txt/cord-342603-k0f33p3l.txt
title:
  Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID‐19

summary:
  Initial data support a high incidence of thromboembolic disease, and especially VTE, in hospitalized COVID-19 patients, as well as poorer outcomes for COVID-19 patients with pre-existing cardiovascular disease [3, 7] . Early reports suggest a high incidence of VTE in hospitalized COVID-19 patients, particularly those with severe illness, that is similar to the high VTE rates observed in patients with other viral pneumonias, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS-CoV)


id: cord-324245-cfiekxr4
author: Giorgi-Pierfranceschi, Matteo
date: 2020-08-25
extension: .txt
mime: text/plain
words: 3775
sentence: 144
flesch: 33
cache: cache/cord-324245-cfiekxr4.txt
txt: txt/cord-324245-cfiekxr4.txt
title:
  Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study

summary:
  Prophylaxis in Medical Patients with Enoxaparin Study Group Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients Investigators ARTEMIS (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo-controlled trial Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations Venous thromboembolism prophylaxis in critically ill patients Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis VTE incidence and risk factors in patients with severe sepsis and septic shock A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score Scoring systems for estimating risk of venous thromboembolism in hospitalized medical patients Publication WHO REFERENCE NUMBER: WHO/COVID-19/laboratory/2020 Ultrasound for lower extremity deep venous thrombosis: multidisciplinary recommendations from the society of radiologists in ultrasound consensus conference Detection of deep-vein thrombosis by real-time B-mode ultrasonography Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Autopsy findings and venous thromboembolism in patients with COVID-19 Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study Prevent Medical Thromboprophylaxis Study Group, Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients Cao Bin (2020) VTE represents a frequent and potentially fatal complication in hospitalized patients.


id: cord-353692-2zotqreu
author: Dong, Fen
date: 2020-05-07
extension: .txt
mime: text/plain
words: 4377
sentence: 188
flesch: 29
cache: cache/cord-353692-2zotqreu.txt
txt: txt/cord-353692-2zotqreu.txt
title:
  Effect on Thromboprophylaxis among Hospitalized Patients Using a System-wide Multifaceted Quality Improvement Intervention: Rationale and Design for a Multicenter Cluster Randomized Clinical Trial in China

summary:
  Due to chronology of individual patient recruitment after hospital randomization in clustered randomization trial 28 , this study is prone to selection bias J o u r n a l P r e -p r o o f 22 / 40 induced by unblinded recruiters or patients who are informed or aware of hospital allocation. A multidisciplinary group of hospital staff (doctors, nurses, administrators, pharmacists, etc) from a wide range of departments will be engaged to carry out the QI.


id: cord-262125-0vajpo98
author: Doyle, Andrew J.
date: 2020-10-08
extension: .txt
mime: text/plain
words: 953
sentence: 31
flesch: 31
cache: cache/cord-262125-0vajpo98.txt
txt: txt/cord-262125-0vajpo98.txt
title:
  Updated hospital associated venous thromboembolism outcomes with 90-days follow-up after hospitalisation for severe COVID-19 in two UK critical care units

summary:
  Our guidance for thromboprophylaxis was based originally on NICE guidance for medical patients using dalteparin that was prescribed according to weight and renal function unless contraindicated in all patients. Our two centres have previously described the early in-patient incidence of venous thromboembolism (VTE) at the peak of the COVID-19 outbreak in the United Kingdom1,2.


id: cord-339695-3ij5pjjy
author: Nopp, Stephan
title: Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
date: 2020-09-25
extension: .txt
mime: text/plain
words: 4717
sentence: 190
flesch: 36
cache: cache/cord-339695-3ij5pjjy.txt
txt: txt/cord-339695-3ij5pjjy.txt
summary:
  All rights reserved Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography Venous Thromboembolism in Critically Ill Patients with Covid-19: Results of a Screening Study for Deep Vein Thrombosis Clinical Characteristics of Covid-19 in Remdesivir for the Treatment of Covid-19 -Preliminary Report Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study Anakinra for severe forms of COVID-19: a cohort study Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 ( Therefore, the true underlying burden of VTE in COVID-19 patients is still not fully understood.


id: cord-297001-4g3wb8qi
author: Tal, Shir
title: Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?
date: 2020-05-12
extension: .txt
mime: text/plain
words: 4638
sentence: 203
flesch: 44
cache: cache/cord-297001-4g3wb8qi.txt
txt: txt/cord-297001-4g3wb8qi.txt
summary:
  In view of the high thromboembolic risk in patients with COVID-19 despite anticoagulation treatment [14] , and in view of the thrombotic coagulopathy and extremely high D-dimers with no evidence of clinical bleeding in COVID-19 patients, some institutes like our own recommend considering higher prophylactic doses of anticoagulation such as enoxaparin 0.5 mg/kg b.i.d. or enoxaparin 1mg/kg once daily. In addition, antiphospholipid antibodies that can arise transiently in patients with critical illness and various infections may possibly develop among COVID-19 patients as well.


id: cord-324265-j3v3i8vm
author: Marietta, Marco
title: COVID-19, coagulopathy and venous thromboembolism: more questions than answers
date: 2020-07-11
extension: .txt
mime: text/plain
words: 5042
sentence: 192
flesch: 32
cache: cache/cord-324265-j3v3i8vm.txt
txt: txt/cord-324265-j3v3i8vm.txt
summary:
  The severity of the derangement of coagulation parameters in COVID-19 patients has been associated with a poor prognosis, and the use of low molecular weight heparin (LMWH) at doses registered for prevention of venous thromboembolism (VTE) has been endorsed by the World Health Organization and by Several Scientific societies. This review is particularly focused on four clinical questions: What is the incidence of VTE in COVID-19 patients?


id: cord-288626-7bp92xyo
author: Spyropoulos, Alex C.
date: 2020-06-30
extension: .txt
mime: text/plain
words: 1272
sentence: 43
flesch: 31
cache: cache/cord-288626-7bp92xyo.txt
txt: txt/cord-288626-7bp92xyo.txt
title:
  Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients

summary:
  Rivaroxaban with or without aspirin in stable cardiovascular disease Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN Study In: The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients Venous thromboembolism and atherothrombosis: an integrated approach.


id: cord-274542-fpzk5k79
author: Patti, Giuseppe
date: 2020-11-03
extension: .txt
mime: text/plain
words: 5631
sentence: 189
flesch: 26
cache: cache/cord-274542-fpzk5k79.txt
txt: txt/cord-274542-fpzk5k79.txt
title:
  Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology

summary:
  Bruxelles: European Society of Cardiology Efficacy of various treatment modalities for nCOV-2019: a systematic review and metaanalysis Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19 Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture Treatment with lopinavir/ ritonavir or interferon-β1b improves outcome of MERSCoV infection in a nonhuman primate model of common marmoset Treatment of Middle East respiratory syndrome with a combination of lopinavirritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis Novel coronavirus treatment with ribavirin: groundwork for evaluation concerning COVID-19 Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 Dexamethasone in hospitalized patients with Covid-19-preliminary report Tocilizumab treatment in COVID-19: a single center experience Antithrombotic treatments in patients with SARS-CoV-2 infection: from current evidence to reasonable recommendations-a position paper from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology Edoxaban for the treatment of cancer-associated venous thromboembolism Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) Infection Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment Current overview on hypercoagulability in COVID-19 COVID-19 and thrombotic or thromboembolic disease: Finally, general practitioners were not able to immediately assist patients on VKAs in need of INR adjustments, as they were also fully involved in the management of COVID-19 patients.


id: cord-296607-h2zwlyz7
author: Watson, Ryan A.
date: 2020-06-09
extension: .txt
mime: text/plain
words: 7740
sentence: 315
flesch: 32
cache: cache/cord-296607-h2zwlyz7.txt
txt: txt/cord-296607-h2zwlyz7.txt
title:
  Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system

summary:
  COVID-19 patients may present with hemodynamic instability and increased biomarkers of cardiac injury, specifically troponin and B-Type Natriuretic Peptide. COVID-19 patients, commonly present with shortness of breath secondary to viral pneumonia with critically ill patients progressing to acute respiratory distress syndrome (ARDS).


id: cord-277146-4a4vz36h
author: Aggarwal, Mukul
title: Hemostatic Abnormalities in COVID-19: An Update
date: 2020-08-11
extension: .txt
mime: text/plain
words: 4633
sentence: 228
flesch: 37
cache: cache/cord-277146-4a4vz36h.txt
txt: txt/cord-277146-4a4vz36h.txt
summary:
  Lupus anticoagulant is frequent in patients with Covid-19 High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Arterial thromboembolic complications in COVID-19 in low risk patients despite prophylaxis Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 COVID-19: towards understanding of pathogenesis Clinical features of patients infected with 2019 novel coronavirus in Wuhan COVID-19: consider cytokine storm syndromes and immunosuppression Cytokine storm and sepsis disease pathogenesis The coagulopathy of acute sepsis Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Clinical characteristics of coronavirus disease 2019 in China Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Pathological findings of COVID-19 associated with acute respiratory distress syndrome Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study Vander Heide RS (2020) Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease Thrombocytopenia and its association with mortality in patients with COVID-19 Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 PROTECT collaborators, the Canadian Critical Care Trials Group, and the Australian, and New Zealand Intensive Care Society Clinical Trials Group (2013) Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes Mechanism of thrombocytopenia in COVID-19 patients COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure Incidence of venous thromboembolism in hospitalised patients with COVID-19 Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome Hypercoagulability of COVID-19 patients in intensive care unit a report of thromboelastography findings and other parameters of hemostasis Prominent changes in blood coagulation of patients with SARS-CoV-2 infection Coagulopathy and antiphospholipid antibodies in patients with Covid-19 International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)


id: cord-283267-72wrzw09
author: Moores, Lisa K.
date: 2020-06-02
extension: .txt
mime: text/plain
words: 8243
sentence: 372
flesch: 35
cache: cache/cord-283267-72wrzw09.txt
txt: txt/cord-283267-72wrzw09.txt
title:
  Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report

summary:
  An updated analysis High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Incidence of venous thromboembolism in hospitalized patients with COVID-19 Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom Risk assessment of venous thromboembolism and bleeding in COVID-19 patients Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: The incidence of VTE in COVID-19 patients is not well defined, but early reports suggest it may be higher than in non-COVID hospitalized patients with similar degrees of illness, even in the presence of prophylactic anticoagulation.


id: cord-312388-pc89ybxw
author: Singhania, Namrata
title: Current Overview on Hypercoagulability in COVID-19
date: 2020-08-04
extension: .txt
mime: text/plain
words: 4218
sentence: 183
flesch: 38
cache: cache/cord-312388-pc89ybxw.txt
txt: txt/cord-312388-pc89ybxw.txt
summary:
  That study also compared patients with COVID-19-associated acute respiratory distress syndrome (ARDS) with a matched cohort of non-COVID-19 ARDS patients and found the rate of PE was higher in COVID-19 patients [11.7% vs. 2.1%; odds ratio (OR) 6.2, 95% CI 1.6-23.4; p < 0.008]. Clinical characteristics of coronavirus disease 2019 in China An atypical presentation of novel coronavirus disease 2019 (COVID-19) COVID-19 and coagulopathy: frequently asked questions Endothelial cell infection and endotheliitis in COVID-19 Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 The factor VIII acute phase response requires the participation of NFκB and C/EBP Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction Hypercoagulability of COVID-19 patients in Intensive Care Unit.


id: cord-326272-ya3r0h1t
author: Dobesh, Paul P.
title: Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID‐19
date: 2020-10-01
extension: .txt
mime: text/plain
words: 8611
sentence: 397
flesch: 41
cache: cache/cord-326272-ya3r0h1t.txt
txt: txt/cord-326272-ya3r0h1t.txt
summary:
  All rights reserved There have also been observational trials that have compared rates of VTE in COVID-19 patients to historical controls without COVID-19 (Table 3) . The rate of PE was 3-fold higher in COVID-19 patients compared to those without, but was also more than 2-fold higher than influenza patients specifically during the same time frame.


id: cord-336000-v88bq4bx
author: Barco, Stefano
date: 2020-09-09
extension: .txt
mime: text/plain
words: 20408
sentence: 818
flesch: 38
cache: cache/cord-336000-v88bq4bx.txt
txt: txt/cord-336000-v88bq4bx.txt
title:
  Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial

summary:
  OVID may increase the level of safety compared to standard of care for study patients because frequent telephone visits are planned (Day 3, 7, 14, 30, 90) . Source data must be available at the site to document the existence of the study participants and substantiate the integrity of study data collected.


id: cord-006870-f5w6fw6q
title: Abstracts Presented at the Neurocritical Care Society (NCS) 15th Annual Meeting
date: 2017-09-19
extension: .txt
mime: text/plain
words: 122395
sentence: 6375
flesch: 46
cache: cache/cord-006870-f5w6fw6q.txt
txt: txt/cord-006870-f5w6fw6q.txt
summary:
  The best model fit was for good outcome (modified Rankin Score 0-2 equivalents) based on % patients with WFNS 4-5 and age (R2=0.54; p<0.001). Decreasing time spent in cervical spinal immobilization could improve patient care by allowing greater access to / range-of-motion of the neck, increasing patient comfort, and decreasing skin breakdown.


id: cord-009997-oecpqf1j
title: 2018 ASPHO ABSTRACTS
date: 2018-03-31
extension: .txt
mime: text/plain
words: 182444
sentence: 8751
flesch: 45
cache: cache/cord-009997-oecpqf1j.txt
txt: txt/cord-009997-oecpqf1j.txt
summary:
  Of included patients, 165 had treatment intensity of 2 (41.0%), 192 of 3 (47.8%) and 45 of 4 (11.2%). After 2 cycles of treatment patient was no longer requiring oxygen and was ambulating without assistance.


# ent

id: cord-336000-v88bq4bx
sid: 265
eid: 2
type: PERSON
entity:
  von thromboembolischen erkrankungen venösen ursprungs bei bettlägerigen medizinischen patienten mit einer akuten erkrankung


